UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

 

July 31, 2003

 

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

 

0-19731

 

94-3047598

(State or other jurisdiction of
incorporation or organization)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

 

 

 

 

 

94404

(Zip Code)

 

 

 

 

 

(650) 574-3000

(Registrant’s telephone number, including area code)

 

 

 

ITEM 7.

FINANCIAL STATEMENTS AND EXHIBITS

 

 

(c)                                  Exhibits

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on July 31, 2003

 

ITEM 9.

REGULATION FD DISCLOSURE (ALSO BEING FILED UNDER NEW ITEM 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION).

 

On July 31, 2003, Gilead Sciences, Inc., a Delaware corporation, issued a press release announcing earnings for the quarter and six months ended June 30, 2003. A copy of the earnings press release is filed as Exhibit 99.1 to this report.

 

Each non-GAAP financial measure presented in the earnings press release is included because our management uses this information to monitor and evaluate on-going operating results and trends excluding certain items.  Our management believes the non-GAAP information is also useful for investors because the in-process research and development charge relating to the acquisition of Triangle Pharmaceuticals, Inc. in January 2003 was the result of a transaction that is unusual due to its nature, size and infrequency.  Consequently, excluding this charge from our operating results provides users of the financial statements an important insight into our operating results and related trends that affect our core business.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GILEAD SCIENCES, INC.

 

(registrant)

 

 

 

/s/John F. Milligan

 

John F. Milligan
Senior Vice President and
Chief Financial Officer

 

 

Date:                    July 31, 2003

 

 

3

 

Exhibit Index

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on July 31, 2003

 

4